Long-term survival after ovarian cancer diagnosis higher than previously thought
the ONA take:
UC Davis researchers reviewed data collected on thousands of patients with ovarian cancer in California and found that survival rates are higher than predicted for most women. In fact, almost one-third of patients survive at least 10 years after diagnosis.
The study confirmed the factors associated with higher survival, such as younger age, early stage, and lower grade tumor at diagnosis; however, it also found a surprising number of survivors who did not meet that criteria. Most survival studies consider 5-year survival or less; this study looked at 10-year survival.
Of the 11,541 patients in the California Cancer Registry, the database used for the study, 3,582 survived more than 10 years. Furthermore, 954 of those survivors had been considered to be at high risk of dying from their disease.
The researchers’ next step is to figure why so many women who are given a poor prognosis beat their odds. Some theories include women with the BRCA1/2 mutation may respond better to chemotherapy, biological differences in women may affect individual outcomes, or some patients may receive more effective treatment than others.
Survival rates for ovarian cancer are higher than predicted for most women.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|